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http://www.springerplus.com/content/3/1/413RESEARCH Open AccessMedication in nursing homes in Alsace:
a preferential list of drugs obtained by consensus
Sophia Hannou1,2, Amélie Rousseau1, Marie-Christine Rybarczyk-Vigouret1 and Bruno Michel1,3*Abstract: In order to improve patient care, OMEDIT (Observatory of drugs, medical devices and therapeutic
innovation) Alsace, conducted a study to develop a Preferential list of Drugs adapted to the Elderly (PDE list) in
nursing homes. The study conducted from December 2011 to June 2012 was organized in 4 phases: 1) creation
of a preliminary list of drugs from those currently used in nursing homes in Alsace, 2) application of a two-round Delphi
process to evaluate the preliminary list involving mobilization of experts from different backgrounds (geriatricians,
general practitioners, pharmacists …), 3) identification of molecules considered in literature as potentially inappropriate,
4) generation of a final PDE list, including information concerning proper use of drugs for prescription and administration.
53 experts participated in the study. In the first round, 338 drugs were on the preliminary list, 246 were considered as
appropriate by experts and 28 as inappropriate. 64 drugs without consensus were submitted to a second round. 32 of
them were considered as inappropriate and 32 others remained on the list with no consensus. These last 32 were
evaluated by OMEDIT and 3 were considered as appropriate drugs for the elderly. Totally, 252 drugs constitute the final
PDE list from our study. The PDE list constitutes a new guide for optimization of both prescription and administration of
drugs in nursing homes and could help reduce misuses and poly-medication, which are constant preoccupations to avoid
adverse drug reactions in elderly.
Key points:
● The study was carried out with the aim to create a Preferential list of Drugs adapted to the Elderly (PDE list) in nursing
homes using a modified Delphi method.
● The PDE list constitutes a new guideline to harmonize practices in nursing homes and to help physicians and nurses to
achieve best possible care management.
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prescription1. Introduction
The European population is living longer than before and
the percentage of the elderly in society is a significant
demographic change, and as a consequence, the part of this
population going to nursing homes is growing. The health
status of these frail and/or dependent patients with various
pathologies often requires the use of several medications.
In this regard, a number of studies have shown that
poly-medication, defined as medication with at least 5
to 8 drugs, is common in the elderly with the highest* Correspondence: bruno.michel@chru-strasbourg.fr
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in any medium, provided the original work is pnumber of drugs taken by those residing in nursing
homes (Maher et al. 2014). With the use of multiple
medications, an increased risk for negative health outcomes
has been described (Maher et al. 2014).
Reducing overuse of drugs in nursing homes, especially
to prevent adverse drug reactions (ADRs), is a major
health concern and constitutes a challenge for every
care giver, even for the most experienced clinicians
(Petrovic et al. 2012). In the elderly, the risk of ADRs
is positively correlated to the number of drugs used.
As an illustration, elderly patients taking 2 drugs face a
13% risk of adverse drug-drug interactions, and this rises
to 38% for 4 drugs and to 82% if 7 or more drugs
are given simultaneously (Leendertse et al. 2008; Beijer &
de Blaey 2002). The ADRs, in the elderly, often lead to
hospitalization and increased expenditure for medical carean Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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rate of ADR-related hospital admissions is 16.6% in
older patients, compared to 4.1% in younger patients
(Beijer & de Blaey 2002).
Besides overuse, other considerations must be
taken into account to render medications and health
conditions secure in the elderly: misuse or under-use
of drugs, respect of dosage, appropriate pharmaceutical
form in case of deglutition problems. Other factors to
be considered are impairment renal or hepatic function
and the clinical characteristics of the patient such as
alteration in cognitive function, urinary incontinence
(Topinkova et al. 2012).
Physicians who are working in nursing homes are
usually not geriatricians. Their workload mostly does
not allow time for in-depth reviews of literature,
which is currently starting to be rich in drug- safety
specific reports and lists of potentially inappropriate
medication (PIM) for the elderly. Considering the
given situation, the idea of guiding the prescription to
treat the main pathologies encountered towards drugs
belonging to an arsenal validated by a panel of recognized
experts was attractive.
This present study was carried out with the aim to
create a preferential list of Drugs adapted to the Elderly


















Figure 1 Presentation of the Delphi process used to generate the premethod. This PDE list was based on personal experience/
opinion of 53 experts and available evidence.
The final goal was to provide a support document to help
health-care professionals (mainly general practitioners, but
also nurses and pharmacists) in nursing homes to set
their own guidelines for one main objective: simplifying
prescription and administration in order to improve the
management of drug therapy in the elderly.
2. Methods
This study was carried out from December 2011 to June
2012 and was conducted by OMEDIT (Observatory of
drugs, medical devices and therapeutic innovation)
Alsace in France. Alsace is a region in France with
1.8 million inhabitants.
The literature contains many different age thresholds
for the definition of the elderly. The threshold of 65 years
with poly-pathologies or 75 years or more were the cut-offs
retained in this study [ANSM (ex Afssaps) 2005].
Study design
The data was collected in 4 phases (Figure 1).
1) Creation of a preliminary list of drugs based on
formularies used in daily practices in nursing homes
in Alsace.ry list (338 drugs)
n formularies 
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evaluate the preliminary list in order to lead to
build a PDE list. This step included:
a) recruitment of experts,
b) creation of a first-round of a survey and subsequently
sending e-mails to the experts,
c) creation of the second-round of the survey based
on results from the first round and receiving
feedback from the panel of experts.
3) Identification of molecules considered in literature
as potentially inappropriate in the preliminary list
and in the PDE list obtained from Delphi process.
4) Generation of the final PDE list containing
appropriate drugs for the elderly based on the
experts’ opinion and combined also with practical
information for the proper use of drugs, in terms of
prescription and administration.2.2. Creation of a preliminary list of drugs commonly
used in nursing homes
An inventory of the available drug formularies used in
nursing homes in Alsace was carried out in December
2011. Drugs present in more than 20% of the formularies
analyzed were selected to be part of the preliminary list
of the study. Specific treatments such as antineoplastic
drugs were excluded from the study.2.3. Application of the Delphi method
The Delphi method, developed by the Rand Corporation
in the 1950s, is a research method allowing a consensus
opinion to be reached among experts through an iterative
and anonymous process known as rounds (Dalkey 1969).
The method uses surveys in order to collect information.
Two rounds were carried out in our study. The responses
from the first round were collected and analyzed; a revised
survey was then submitted to the experts to initiate the
second round.Experts: panel selection
After consulting several healthcare professionals and
scientific societies specialized in the field, a panel of
potential members with recognized expertise was
identified and invited to participate in this study. Care
was taken to select experts from Alsace (44 = experts)
but also from other parts of France (n = 4 experts)
and from neighboring countries (n = 5 experts). These
experts represented 6 different specialties [geriatric
medicine (n = 22), clinical pharmacology (n = 2), general
practice in nursing homes (10), pharmacovigilance
(n = 2) and pharmacy (n = 17 experts, 7 community
pharmacists practicing in nursing homes and 10 hospital
pharmacists].Data collection and analysis
First-round The preliminary list was used to formulate
the first round of the survey which was then sent by
e-mail to the experts. They rated each drug on a five-point
Likert scale, which ranges from a score of 1 (drugs that
can be considered as appropriate for the elderly in nursing
homes) to 5 (drugs that can definitely be considered as
inappropriate in nursing homes) (Matell & Jacoby 1971).
An appropriate drug was defined as an indispensable drug
with a clear-cut benefit in terms of efficacy/safety ratio or
a drug with obvious efficacy.
A score of 3 was considered as neutral (undecided).
After the first round, the mean Likert score and the
corresponding 95% confidence interval (CI) were
determined for each drug. Drugs, for which the upper
bound of the 95% CI was less than 3.0, were classed as
appropriate, while drugs, for which the lower bound
of the 95% CI was greater than 3.0, were classed as
inappropriate drugs for elderly persons. Only the drugs
whose 95% CI was on both sides of 3.0, were evaluated
further by the experts, in the second round of questioning.
During the first-round, experts were also invited to
add comments, to suggest safer or more appropriate
alternative therapeutics.
Second-round The second-round of the survey included
drugs that didn’t reach consensus from round-one with
the results of their scores and any statements added
by the experts. The data were presented anonymously,
enabling the participants to reconsider their previous
responses. The answers provided by the experts in the
second round were evaluated by the same procedure
described above.
2.4. Potentially inappropriate medications in the elderly
Three lists of PIM were used to identify drugs categorized
as inappropriate from the preliminary and the PDE lists
(The American Geriatrics Society 2012 Beers Criteria
Update Expert P 2012; Holt et al. 2010; Laroche et al. 2007).
We had access to two European lists (one from Germany
and one from France) and one list from the American
geriatrics society. Although it was not specifically developed
for European countries, the list from the United States of
America (USA) has already been successfully used to detect
PIM in European countries and it has been recently
updated (Laroche et al. 2007).
2.5. Generation of the final PDE list
The final PDE list was established on the basis of two
rounds of the Delphi process. Drugs considered as
appropriate in nursing homes by experts but qualified
as inappropriate by the literature have been nevertheless
retained in the final PDE list. Information concerning the
proper use of drugs was added for each drug in the list.
Table 1 Distribution of drugs in the preliminary list
according to the ATC* classification
ATC classification system Number of drugs
A. Alimentary tract and metabolism 54
B. Blood and blood forming organs 15
C. Cardiovascular system 59
D. Dermatologicals 26
G. Genito urinary system and sex hormones 12
H. Systemic hormonal preparations 9
J. Anti-infective for systemic use 29
L. Antineoplastics and immunomodulating
agents
5
M. Musculo-skeletal system 20
N. Nervous system 74
P. Antiparasitic products, insecticides and
repellents
0
R. Respiratory system 22
S. Sensory organs 13
*ATC: Anatomic, Therapeutic and Chemical classification.
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ferent sources: European Medicines Agency (EMA),
French national agency of drug security (ANSM, Agence
Nationale de Sécurité du Médicaments et des produits de
santé), French database Thériaque (2014), OMEDIT
Normandy (2014) and pharmaceutical companies.
2.6. Statistical analysis
Statistical calculations were performed with the SAS
program, version 9.1 (SAS Institute Inc Cary, North
Carolina, USA).
3. Results
Figure 1 summarizes the process used to generate the
PDE list.
3.1. Creation of a preliminary list of drugs used in nursing
homes
One hundred and five nursing homes of Alsace were
asked whether they had a formulary of drugs in their
facility. Only 23 nursing homes had formularies, of
which 20 provided a copy of their document. After
reviewing the 20 formularies, we found that they actually
corresponded to 15 different lists of drugs. Indeed, in
some cases, several nursing homes shared the same
formulary. Of the 15 drug formularies, 11 were finally used
for the design of the preliminary list. Three formularies
were excluded because they were consumer reports
without any indications to ensure the proper use of
medications and one corresponded to a list of medications
which had to be avoided in the elderly.
Drugs present in more than 20% of the 11 analyzed
formularies were then chosen to be part of the preliminary
list of our study. Three hundred and thirty eight drugs of
the 591 on the lists were thus selected and the preliminary
list of drugs was constituted. Table 1 shows the distribution
of the 338 molecules of this list according to the
ATC classification (Anatomic, Therapeutic and Chemical
classification).
3.2. Application of the Delphi method
Contacts were established with 50 experts, of whom 48
agreed to participate in the project. The 48 experts
completed all rounds of the survey (from February to
April 2012). Five additional experts, who were subsequently
included by personal communication, then joined the study
during the second-round. Finally, the panel of experts was
composed of physicians, representing two-thirds of the
panel and pharmacists the remaining one-third.
 Based on the results from the first round which
evaluated 338 drugs: 246 molecules of the
preliminary list were judged to be appropriate for
the elderly, 28 drugs were excluded and a consensuscould not be reached for 64 other drugs. Thus, a
further evaluation was needed for these last 64 drugs.
 After the second round: 32 drugs were definitely
considered as inappropriate for the elderly. For
the last 32 drugs, no consensus was obtained
(see Table 2). OMEDIT, identified as a group of
experts, evaluated these latter 32 drugs.
 OMEDIT evaluation: 29 of the 32 drugs were
excluded by OMEDIT Alsace, considering the
existence of therapeutic alternatives validated by
experts during the first round; the remaining 3
drugs [ibuprofen, diclofenac and tramadol] were on
the other hand retained in the list.
During the Delphi process, the experts also suggested
new drugs as possible appropriate medications. Among
proposals made by the experts, 3 suggestions were retained
by OMEDIT Alsace (an antiseptic mouthwash containing
chlorhexidine and chlorobutanol, heparin calcium which is
suitable for people with impaired renal function and a skin
antiseptic containing chlorhexidine). Thus, the Delphi
process finally identified 252 drugs. These constitute the
proposed PDE list presented in the article.
3.3. Potentially inappropriate medications in the elderly
Of the 338 starting molecules (preliminary list of the
study) and the 252 drugs of the PDE list, 68 (20%)
and 30 (12%) were respectively considered as potentially
inappropriate in the elderly according to the 3 PIM lists
mentioned in the methods (The American Geriatrics
Society 2012 Beers Criteria Update Expert P 2012;
Holt et al. 2010; Laroche et al. 2007). Table 3 shows the
Table 2 Drugs for which the experts did not reach a clear
decision after the 2-round Delphi process
ATC* classification system Drug evaluation on the 5-point
Likert scale mean, and 95%
confidence interval
A. Alimentary tract and
metabolism
Glibenclamide 3,17 [2,88; 3,46]
Loperamide 3,12 [2,82; 3,41]
Mebeverine 3,15 [2,89; 3,41]
Metopimazine 3,10 [2,84; 3,36]
Miconazole 3,13 [2,85; 3,42]
Ornithine oxoglurate 3,31 [2,99; 3,64]
Porcine pancreatin 3,18 [2,97; 3,39]
Saccharomyces Boulardii 2,81 [2,50; 3,12]
Sitagliptin 3,17 [2,91; 3,44]
Trimebutine 2,96 [2,70; 3,23]
C. Cardiovascular system
Bisoprolol + hydrochlorothiazide 3,12 [2,88; 3,35]
Spironolactone + furosemide 2,94 [2,67; 3,21]
D. Dermatologicals
Dexpanthenol 3,08 [2,77; 3,39]
Retinol 3,02 [2,78; 3,26]
J. Antiinfectives for systemic use
Fosfomycin 3,33 [2,98; 3,67]
Spiramycin +metronidazole 3,38 [2,52; 3,06]
M. Musculo-skeletal system
Diclofenac 3,02 [2,70; 3,34]
Ibuprofen 3,38 [2,98; 3,60]
N. Nervous system
Acetylleucine 3,02 [2,72; 3,32]
Betahistine 2,96 [2,66; 3,26]
Clonazepam 3,21 [2,91; 3,52]
Duloxetine 2,76 [2,51; 3,02]
Fluoxetine 3,18 [2,93; 3,43]
Haloperidol 2,88 [2,60; 3,16]
Hydroxyzine 3,08 [2,75; 3,40]
Lorazepam 3,13 [2,82; 3,44]
Lysine acetylsalicylate 3,24 [2,95; 3,53]
Milnacipran 2,96 [2,70; 3,21]
Tianeptine 3,24 [2,97; 3,50]
Tramadol 2,94 [2,67; 3,20]
Tramadol + acetaminophen 3,14 [2,86; 3,41]
S. Sensory organs
Dexamethasone + neomycin +
polymyxin B
2,90 [2,62; 3,18]
*ATC: Anatomic, Therapeutic and Chemical classification.
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process and considered as PIM by the literature. Of
the 30 molecules present in the PDE list, 7 of them
were considered as potentially inappropriate only beyond
a certain daily dose; 8 could be used with caution in view
of the literature and one was proposed in the form of eye
drops and not for systemic use.
On the other hand, during the Delphi process, the
experts identified 31 additional molecules as potentially
inappropriate in the elderly and there has been no prior
mention of these in the literature (see Table 4).
3.4. Generation of the final PDE list
As mentioned above, the PDE list contains 252 drugs. A
version of the list is shown in Table 5. To improve the
effective use of the PDE list, valuable information for daily
practices were added [the list with specific information
concerning each drug is available at http://www.ars.alsace.
sante.fr/Liste-preferentielle-de-medica.144691.0.html (lan-
guage: French)]. These data were intended to guide the
physician in his prescription and the nurses in drug
administration. For each molecule, the existence of
generic drugs was specified, all dosages were mentioned,
galenic forms commonly encountered were listed (tablets,
capsules, oral solutions …). For dry oral forms, the
possibility of crushing the tablets or opening the capsules
was described. The shelf life of oral liquid forms after first
opening the container was indicated. Sugar content,
sodium, potassium and ethanol were also indicated.
For the 30 drugs in the PDE list considered as poten-
tially inappropriate for the elderly by the literature, all
the criteria developed in the reviews were reproduced
and put forth such as arguments, clinical monitoring,
therapeutic alternatives.... Warnings were indicated
when the state of renal or hepatic functions needed
to be taken into account for prescription.
4. Discussion
We have proposed a preferential list of drugs adapted to
the elderly in nursing homes (PDE list) that includes
molecules and their presentation forms having a utility,
a favorable balance risk/benefit or a well-established use
in this particular population. This list is based upon
methods that included : i) creating a preliminary list
from drug formularies used in daily practices in nursing
homes in Alsace, ii) soliciting experts through a Delphi
process, iii) identifying molecules considered in literature
as PIM. Thus, the PDE list is the result of multifaceted
interventions to achieve optimal results for prescribing
drugs for elderly people.
The field for optimization of drug prescriptions in
the elderly has received great attention in the last few
years. A range of strategies has been implemented to
precisely define inappropriate practices in older people
Table 3 Drugs considered as appropriate in the elderly by
the experts but inappropriate according to the literature
ATC* classification system Drug evaluation on the 5-point
Likert scale mean and 95%
confidence interval
A. Alimentary tract and
metabolism
Insulin, sliding scale
Types of insulin and analogues for
injection:
Ultrafast-acting 1,59 [1,33; 1,85]




Gelified liquid paraffin 2,39 [2,01; 2,77]
Scopolamine 2,39 [2,01; 2,77]
B. Blood and blood forming
organs




Amiodarone 1,81 [1,52; 2,10]
Digoxin (doses > 0,125 mg/d or
[c]ser > 1.2 ng/ml)
2,10 [1,74; 2,46]
Nicardipine 2,18 [1,85; 2,52]
Sotalol 2,26 [1,99; 2,52]
Spironolactone (doses > 25 mg/d) 1,76 [1,51; 2,01]
J. Anti-infectives for systemic use
Nitrofurantoin 2,45 [2,08; 2,83]
M. Musculo-skeletal system
Tiemonium 2,20 [1,82; 2,57]
N. Nervous system
Alprazolam (doses > 2 mg/d) 2,10 [1,81; 2,40]
Carbamazepine 2,51 [2,18; 2,84]
Citalopram 1,96 [1,71; 2,20]
Clozapine 2,38 [2,04; 2,71]
Escitalopram 1,92 [1,67; 2,17]
Loxapine 2,64 [2,31; 2,96]
Mirtazapine 2,50 [2,17; 2,82]
Olanzapine (doses > 10 mg) 2,23 [1,89; 2,56]
Oxazepam (doses > 60 mg/d) 2,04 [1,74; 2,34]
Paroxetine 1,89 [1,67; 2,11]
Piribedil 2,63 [2,28; 2,96]
Risperidone 1,98 [1,73; 2,23]
Sertraline 2,11 [1,85; 2,37]
Venlafaxine 2,27 [1,97; 2,57]
Zolpidem (doses > 5 mg/d) 2,35 [2,06; 2,65]
Zopiclone (doses > 3,5 mg/d) 2,32 [2,00; 2,63]
Table 3 Drugs considered as appropriate in the elderly by
the experts but inappropriate according to the literature
(Continued)
S. Sensory organs
Indomethacin (if oral route) 2,13 [1,89; 2,37]
*ATC: Anatomic, Therapeutic and Chemical classification.
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made in the USA, in Germany and in France to identify
PIMs among drugs that are available in each of these
countries (The American Geriatrics Society 2012
Beers Criteria Update Expert P 2012; Holt et al. 2010;
Laroche et al. 2007) in order to be used with caution. The
best known screening tool to reduce inappropriate
prescribing is the Beers list which has been recently
updated by the American geriatrics society (The
American Geriatrics Society 2012 Beers Criteria Update
Expert P 2012). These lists can also be called “negative
lists”. By contrast, the issue of appropriate medication per
se is poorly documented. The use of lists containing drugs
with a benefit-to-risk ratio acceptable in the elderly is
rarely proposed as an approach that can be used to ensure
the appropriateness of prescribing, and as far as we know,
our PDE list constitutes the first data ever published in
France.
The methodology used for building the PDE list began
with an inventory of the available drug formularies used
in nursing homes in Alsace. Eleven drug formularies
were analyzed, 591 drugs were counted. The comparison
of the content of these formularies and the data obtained
from Alsatian general health insurance concerning
reimbursed drugs for the elderly authorized us to state
that these 591 drugs were representative of those used in
the whole region.
For practical reasons, all the molecules were not
reviewed by experts. If the drug was present in 20% of
the analyzed formularies- 20% thus being set as the
arbitrary cut-off percentage- it was then included to be
part of the preliminary list. The main argument for the
determination of the deciding percentage was based on
the idea that a molecule present in only one or two
formularies responded to needs associated with specific
care management.
The Delphi method is a consensus technique used and
validated in various health domains such as various
clinical practices (Jones & Hunter 1995). This approach
allowed us to submit the preliminary list to a panel
of experts. The subjectivity of the assessment by a
consensus of experts is obvious, but can be overcome
by requesting a large number of experts. In our case,
48 experts participated in the first round of questioning,
and 53 completed the second round. Moreover, the PDE
list combined this data with the opinion of practitioners
Table 4 Drugs considered as inappropriate in the elderly by the experts but appropriate according to the literature
ATC: Anatomic, Therapeutic and Chemical classification Drug evaluation on the 5-point Likert scale Mean and 95% confidence interval
First round Second round
A. Alimentary tract and metabolism
Acarbose 2,97 [2,64; 3,31] Second round 3,27 [3,02; 3,52] Excluded
Anethole trithione 2,88 [2,55; 3,21] Second round 3,33 [3,07; 3,58] Excluded
Glimepiride 2,85 [2,52; 3,17] Second round 3,28 [3,01; 3,57] Excluded
Magnesium aspartate 3,04 [2,69; 3,39] Second round 3,68 [3,42; 3,94] Excluded
Magnesium carbonate 3,02 [2,66; 3,37] Second round 3,59 [3,31; 3,87] Excluded
Magnesium lactate + pyridoxine 3,23 [2,90; 3,57] Second round 3,72 [3,47; 3,97] Excluded
Nifuroxazide 3,43 [3,12; 3,74] Excluded
Ranitidine 2,93 [2,60; 3,26] Second round 3,38 [3,12; 3,64] Excluded
Ursodeoxycholic acid 2,85 [2,48; 3,21] Second round 3,27 [3,00; 3,54] Excluded
B. Blood and blood forming organs
Tranexamic acid 2,82 [2,47; 3,18] Second round 3,27 [3,01; 3,53] Excluded
C. Cardiovascular system
Cibenzoline 2,97 [2,65; 3,30] Second round 3,24 [3,02; 3,45] Excluded
Diosmin 3,78 [3,41; 4,16] Excluded
Fenofibrate 3,06 [2,75; 3,38] Second round 3,46 [3,21; 3,72] Excluded
Trimetazidine 3,80 [3,45; 4,16] Excluded
D. Dermatologicals
Terbinafine 2,71 [2,33; 3,08] Second round 3,34 [3,08; 3,6] Excluded
G. Genito-urinary system and sex hormones
Neomycin + nystatin + metronidazole 3,24 [2,92; 3,56] Second round 3,47 [3,2; 3,74] Excluded
H. Systemic hormonal preparations
Salmon calcitonin 3,13 [2,79; 3,49] Second round 3,47 [3,2; 3,74] Excluded
J. Anti-infectives for systemic use
Telithromycin 2,92 [2,61; 3,22] Second round 3,52 [3,28; 3,77] Excluded
M. Musculo-skeletal system
Celecoxib 3,82 [3,51; 4,14] Excluded
Chondroitin sulfate 3,28 [2,91; 3,65] Second round 3,88 [3,60; 4,10] Excluded
Dantrolene 3,23 [2,90; 3,65] Second round 3,36 [3,11; 3,62] Excluded
Strontium ranelate 3,35 [2,98; 3,72] Second round 3,82 [3,55; 4,09] Excluded
Thiocolchicoside 3,15 [2,78; 3,51] Second round 3,38 [3,10; 3,67] Excluded
Avocado and soybean oil 3,46 [3,08; 3,85] Excluded
N. Nervous system
Acetaminophen + caffeine + opium 3,06 [2,74; 3,39] Second round 3,32 [3,04; 3,59] Excluded
Buprenorphine 3,21 [2,90; 3,52] Second round 3,38 [3,39; 3,94] Excluded
Pipamperone 3,48 [3,15; 3,80]
Selegiline 3,07 [2,74; 3,39] Second round 3,49 [3,26; 3,71] Excluded
Tropatepine 3,32 [2,95; 3,69] Second round 3,62 [3,34; 3,90] Excluded
R. Respiratory system
Prednisolone + naphazoline 3,44 [3,11; 3,77] Excluded
Theophylline 3,41 [3,06; 3,77] Excluded
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Table 5 Medication in the elderly: the preferential list of drugs obtained by consensus from a panel of 53 experts
(Delphi process)
A. Alimentary tract and metabolism B. Blood and blood
forming organs
C. Cardiovascular system
Ascorbic acid Acenocoumarol Acebutolol Nicorandil
Calcium carbonate Acetylsalicylic acid Amiodarone Perindopril
Calcium carbonate + colecalciferol Calcium heparin Amlodipine Perindopril + indapamide
Chlorhexidine + chlorobutanol Clopidogrel Atenolol Pravastatin
Colecalciferol Cyanocobalamin Atorvastatin Propranolol
Diosmectite Enoxaparin Benazepril + hydrochlorothiazide Ramipril
Domperidone Ferrous fumarate Bisoprolol Rosuvastatin
Ergocalciferol Ferrous sulfate Bumetanide Simvastatin
Esomeprazole Ferrous sulphate + folic acid Candesartan Sotalol
Gliclazide Fluidione Carvedilol Spironolactone
Insulins: ultra-fast acting, Folic acid Celiprolol Spironolactone + altizide
fast-acting,
intermediate - acting intermediate-acting
combined with fast-acting, long –acting
Lactulose Fondaparinux Cicletanine Valsartan
Lanzoprazole Phytomenadione Digoxin Valsartan + hydrochlorothiazide
Liquid paraffin Tinzaparin Diltiazem Verapamil
Macrogol Warfarin Enalapril Zinc oxide + titanium dioxide +
carrageenane
Macrogol in combination with
potassium chloride, sodium chloride
and sodium bicarbonate
Furosemide Zinc oxide + titanium dioxide +
carrageenane + lidocaine
Metformin Glyceryl nitrate (oral)









A. Alimentary tract and metabolism C. Cardiovascular system
Scopolamine Lisinopril + hydrochlorothiazide
Sodium bicarbonate + alginic acid Losartan









Aciclovir Fusidic acid Alfuzosin Betamethasone
Amorolfine Galen’s wax Cyproterone Carbimazole
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Table 5 Medication in the elderly: the preferential list of drugs obtained by consensus from a panel of 53 experts
(Delphi process) (Continued)
Betamethasone Glycerol + vaseline + liquid
paraffin
Dutasteride Glucagon
Betamethasone + salicylic acid Hydrocortisone Econazole Hydrocortisone
Bifonazole Ketoconazole Metronidazole Levothyroxine sodium
Calcipotriol Povidone-iodine Povidone-iodine Methylprednisolone
Calcipotriol + betamethasone Sodium hypochlorite Promestriene Prednisolone
Chlorhexidine + benzalkonium
chloride + benzylic alcohol
Triethanolamine Serenoa repens Prednisone
Ciclopirox Vaseline Tamsulosin
Clobetasol Zinc oxide Trospium
Desonide Zinc oxide + fish liver oil
Econazole Zinc oxide + glycerol + talcum
powder





Aciclovir Fluconazole Anastrozole Alendronic acid
Amoxicillin Fusidic acid Bicalutamide Alendronic acid + colecalciferol
Amoxicillin + clavulanic acid Levofloxacin Letrozole Allopurinol
Amphotericin B Metronidazole Leuprorelin Clodronic acid
Azithromycin Nitrofurantoin Tamoxifen Colchicine + tiemonium +
opium
J. Anti-infectives for systemic use J. Anti-infectives for
systemic use
M. Musculo-skeletal system
Cefixime Norfloxacin Diclofenac (topic use)
Cefpodoxime Ofloxacin Diclofenac (oral use)
Ceftriaxone Oseltamivir Ibuprofen






N. Nervous system N. Nervous system R. Respiratory system S. Sensory organs
Acetaminophen Mirtazapine Acetylcysteine Acetazolamide
Alprazolam Nefopam Beclometasone Artificial tears
Carbamazepine Olanzapine Budesonide Carbomers
Citalopram Oxazepam Carbocisteine Dexamethasone +
oxytetracycline
Clozapine Paroxetine Desloratadine Indometacin
Codeine + acetaminophen Piribedil Fenoterol + ipratropium Latanoprost
Donepezil Pramipexole Formoterol Ofloxacin
Entacapone Pregabalin Helicidine Pilocarpine
Escitalopram Risperidone Ipratropium bromide Retinol
Fentanyl Rivastigmine Levocetirizine Rifamycin
Gabapentin Ropinirole Loratadine Timolol
Galantamine Sertraline Montelukast Xylene
Hydrochloride morphine Fast –acting Morphine sulfate Salbutamol
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Table 5 Medication in the elderly: the preferential list of drugs obtained by consensus from a panel of 53 experts
(Delphi process) (Continued)
Lamotrigine Long-actingMorphine sulfate Salmeterol + fluticasone
Levodopa + decarboxylase inhibitor Tiapride Terbutaline
Levodopa + decarboxylase inhibitor + COMT
inhibitor
Tramadol + acetaminophen Tiotropium bromide
Lidocaine Valproic acid Tixocortol





The detailed list is available at http://www.ars.alsace.sante.fr/Liste-preferentielle-de-medica.144691.0.html (language: French); presentation of drugs according to ATC:
Anatomic, Therapeutic and Chemical classification.
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elderly patients. These experts represented different
specialties and were from different parts of France and
Europe, in order to give a large overview of the practices.
Finally, experts were consulted separately, hence they were
not able to discuss together but were capable of adding
commentaries in order to communicate their ideas
between both rounds. This approach allowed experts
to express their opinions independently and confidentially
without any peer-pressure or conflicts of judgement that
may occur during a face-to-face meeting. Therefore, we
are confident that drugs listed here, are definitely regarded
as useful in daily practices by a large and diverse group of
specialists.
In our study, 30 drugs from the PDE list were considered
as potentially inappropriate in view of the published studies
(The American Geriatrics Society 2012 Beers Criteria
Update Expert P 2012; Holt et al. 2010; Laroche et al. 2007).
We however decided to keep these drugs in the PDE
list and decided to clearly identify them as potentially
inappropriate as a reminder for closer monitoring of
these 30 drugs. On the other hand, experts in our study
excluded 31 molecules which are not cited in the literature
as inappropriate. Some of them have restricted indica-
tions or seem to be unnecessary in nursing homes:
tranexamic acid, calcitonin, dantrolene, ursodeoxycholic
acid, cibenzoline are examples. Others present a lack
of interest: avocado and soybean oil, chondroitin
sulfate, magnesium. Finally, some molecules present an
unfavorable benefit-to-risk ratio: terbinafine, theophylline,
ranitidine, strontium ranelate and acarbose. The differ-
ences between the published PIM lists and our results
could reflect the use of different methodological approaches,
the subjectivity of assessments obtained by consensus
among experts, the pharmaceutical supply available in
different countries. It should also be noted that
significant differences exist between the PIM lists pub-
lished so far (The American Geriatrics Society 2012Beers Criteria Update Expert P 2012; Holt et al. 2010;
Laroche et al. 2007).
Concerning the administration of drugs in the elderly,
as mentioned by Caussin et al. (Caussin et al. 2012),
there is an enormous potential for improvement in
drugs safety and effectiveness. In geriatrics, it is frequent
to crush pills or simply open capsules so that patients
presenting problems swallowing and/or behavior issues
may take the medicines more easily. In the study
mentioned above, 42% of crushed drugs had a galenic
presentation which did not allow crushing. These practices,
marked by frequent errors, may significantly alter the
effectiveness of drugs, their pharmacokinetics and even
could lead to toxic effects for both patients and caregivers.
All classes of drugs are concerned. To avoid these potential
iatrogenic and professional risks, the PDE list indicates
clearly which drugs should not be crushed and, in those
cases, suggests alternative measures.
Finally, the PDE list constitutes a general guide for the
optimization of both prescription and administration
of drugs in nursing homes and this could help reduce
misuses and poly-medication, both of which are constant
preoccupations to avoid ADRs.
Nevertheless, this PDE list has some limitations. First
of all, it is important to concede that the PDE list was
built from Alsatian data. However, physicians from other
French regions should not encounter any major problems
adopting this tool in their nursing homes. Solicited experts
belong to national professionals and scientific societies,
some of them coming from different other regions of
France. This guaranteed that local prescribing practices
did not overly influence the development of the list. On
the other hand, the PDE list has limited applicability for
international use. Country-specific prescribing trends,
disease epidemiology, differences in drug availability must
not be ignored.
Secondly, the PDE list is focused on medication in
nursing homes. The extension of the study to elderly in
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important steps in the updating of the PDE list.
Thirdly, this PDE list should not be used without
adequate clinical expertise. For a given patient, a benefit-
to-risk ratio for each drug has to be assessed considering
clinical conditions, comorbidities, functional status, other
drugs taken and prognosis. Further, the issue of prescrib-
ing appropriateness, in its broader sense, must encompass
steps in favor of non-drug approaches (beneficial drug
omission) and include also patients’ preferences to achieve
optimal results (Spinewine et al. 2007).
Fourthly, the PDE list could be controversial because
of the limitations imposed by this list to the prescribing
physician. It can be argued that the PDE list is a starting
tool. Specific adaptations conducted within each nursing
home in collaboration with physicians, pharmacist, nurses,
and possibly administrative directors, are a suitable
response to allow the intelligent and judicious adoption of
the PDE list.5. Conclusion
Establishing a list of drugs to be used preferentially in
nursing homes is written in the French Code of Public
Health (articles L. 313–12 and L. 5126-6-1). It has to be
developed in each nursing home in a multidisciplinary
context by including coordinating physician, pharmacist
and general practitioners. As we can see in this article
only few Alsatian nursing homes have developed their
own formularies.
The PDE list constitutes a unique and starting guideline
and can by no means be enforced by law but it can be
used mostly to harmonize practices in nursing homes and
to help physicians and nurses to achieve best possible care
management. We expect that the PDE list will have
to be regularly reviewed to be fully useful to health
professionals. A further challenge to facilitate the
adoption of the PDE list will be to demonstrate that
implementation of this tool, adjusted to the needs of
nursing homes, will result in objective and quantifiable
improvements in the management of older people. We
are currently completing a randomized controlled study
among 10 nursing homes in Alsace to assess these issues
in terms of clinical and economic outcomes.
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